Kisspeptin‐54 Levels are increased in Patients with Colorectal Cancer

• DOI: 10.1007/s00268-012-1636-7
• Publication Date: 2012-05-02T18:45:14Z
• Authors: Emel Canbay; Arzu Ergen; Dursun Bugra; Sumer Yamaner; Ilhan Yaylim Eraltan; Yilmaz Buyukuncu; Turker Bulut
• Keywords: Kisspeptin

AbstractBackgroundRecent studies have demonstrated that Kisspeptin, the product of the metastasis suppressor gene KiSS‐1, could have a role in tumor progression and invasion. In this pilot study, we investigated the association of plasma Kisspeptin‐54 level with colorectal cancer (CRC).MethodsPlasma Kisspeptin‐54 levels were quantified using enzyme‐immunoassay (EIA) kits from blood samples of 81 patients with CRC at their initial staging and 59 age‐matched healthy controls.ResultsPlasma Kisspeptin‐54 levels were significantly higher in CRC patients (86.2 ± 20.5) than in controls (49 ± 12.7; p < 0.005). The cutoff value for Kisspeptin‐54 detection was determined as 46 ng/ml, and area under curve (AUC) value was 0.766 with sensitivity 63 %, specificity 81.4 %, positive predictive value 82.2 %, negative predictive value 61.5 %, positive likelihood ratio 3.38, and negative likelihood ratio 0.46. Increased plasma Kisspeptin‐54 levels were significantly correlated with nodal involvement of CRC (Spearman, rs = 0.345, p = 0.002). Kisspeptin‐54 was also found to be an independent predictive marker for lymph node metastases of CRC (p = 0; Exp(B): 2.053; 95 % CI, 1.255‐2.851).ConclusionsOur results reveal that plasma Kisspeptin‐54 measurement could be a useful diagnostic and prognostic parameter for CRC. Further prospective evaluation is needed to validate these findings and to establish the clinical usefulness of Kisspeptin‐54 for CRC diagnostics.